NasdaqGM:ZYNE

Stock Analysis Report

Executive Summary

Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company.

Snowflake

Fundamentals

Flawless balance sheet with high growth potential.

Risks

  • Zynerba Pharmaceuticals has significant price volatility in the past 3 months.

Share Price & News

How has Zynerba Pharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

2.2%

NasdaqGM:ZYNE

-1.8%

US Pharmaceuticals

-1.0%

US Market


1 Year Return

78.3%

NasdaqGM:ZYNE

-6.6%

US Pharmaceuticals

-0.4%

US Market

ZYNE outperformed the Pharmaceuticals industry which returned -6.6% over the past year.

ZYNE outperformed the Market in United States of America which returned -0.4% over the past year.


Share holder returns

ZYNEIndustryMarket
7 Day2.2%-1.8%-1.0%
30 Day3.7%-3.5%-3.3%
90 Day-22.8%-3.8%0.8%
1 Year78.3%78.3%-4.3%-6.6%1.9%-0.4%
3 Year13.5%13.5%7.9%0.6%39.4%30.4%
5 Yearn/a22.9%10.0%54.2%37.1%

Price Volatility Vs. Market

How volatile is Zynerba Pharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Zynerba Pharmaceuticals undervalued based on future cash flows and its price relative to the stock market?

>50%

Discount to future cash flow value


Intrinsic Value Based on Future Cash Flows

Zynerba Pharmaceuticals's share price is below the future cash flow value, and at a moderate discount (> 20%).

Zynerba Pharmaceuticals's share price is below the future cash flow value, and at a substantial discount (> 40%).


Price Based on Earnings

Zynerba Pharmaceuticals is loss making, we can't compare its value to the US Pharmaceuticals industry average.

Zynerba Pharmaceuticals is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Zynerba Pharmaceuticals, we can't assess if its growth is good value.


Price Based on Value of Assets

Zynerba Pharmaceuticals is good value based on assets compared to the US Pharmaceuticals industry average.


Next Steps

Future Growth

How is Zynerba Pharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 6 analysts?

67.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Zynerba Pharmaceuticals's revenue is expected to grow significantly at over 20% yearly.

Zynerba Pharmaceuticals's earnings are expected to grow significantly at over 20% yearly.

Zynerba Pharmaceuticals's revenue growth is expected to exceed the United States of America market average.

Zynerba Pharmaceuticals's earnings growth is expected to exceed the United States of America market average.

Zynerba Pharmaceuticals's earnings growth is expected to exceed the low risk savings rate of 2.7%.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if Zynerba Pharmaceuticals will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.


Next Steps

Past Performance

How has Zynerba Pharmaceuticals performed over the past 5 years?

-35.7%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Zynerba Pharmaceuticals does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare Zynerba Pharmaceuticals's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Zynerba Pharmaceuticals's 1-year growth to the US Pharmaceuticals industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Zynerba Pharmaceuticals has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if Zynerba Pharmaceuticals has efficiently used its assets last year compared to the US Pharmaceuticals industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Zynerba Pharmaceuticals improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is Zynerba Pharmaceuticals's financial position?


Financial Position Analysis

Zynerba Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Zynerba Pharmaceuticals has no long term commitments.


Debt to Equity History and Analysis

Zynerba Pharmaceuticals's level of debt (-0%) compared to net worth is satisfactory (less than 40%).

The level of debt compared to net worth has been reduced over the past 5 years (8.2% vs -0% today).


Balance Sheet

Low level of unsold assets.

Debt is not covered by short term assets, assets are -4551.1x debt.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Zynerba Pharmaceuticals has sufficient cash runway for more than 3 years based on current free cash flow.

Zynerba Pharmaceuticals has sufficient cash runway for 2.6 years if free cash flow continues to grow at historical rates of 20% each year.


Next Steps

Dividend

What is Zynerba Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Zynerba Pharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Zynerba Pharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Zynerba Pharmaceuticals has not reported any payouts.

Unable to verify if Zynerba Pharmaceuticals's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Zynerba Pharmaceuticals has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Zynerba Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

4.8yrs

Average management tenure


CEO

Armando Anido (61yo)

4.8yrs

Tenure

US$2,001,096

Compensation

Mr. Armando Anido, MBA, has been the Chairman and Chief Executive Officer of Zynerba Pharmaceuticals, Inc. since October 2014. Mr. Anido has been Director of SCYNEXIS, Inc. since January 21, 2019. He has m ...


CEO Compensation Analysis

Armando's remuneration is higher than average for companies of similar size in United States of America.

Armando's compensation has been consistent with company performance over the past year, both up more than 20%.


Management Age and Tenure

4.8yrs

Average Tenure

61yo

Average Age

The tenure for the Zynerba Pharmaceuticals management team is about average.


Board Age and Tenure

4.0yrs

Average Tenure

62.5yo

Average Age

The tenure for the Zynerba Pharmaceuticals board of directors is about average.


Insider Trading

No 3 month open market individual insider trading information.


Recent Insider Transactions

BuyUS$32,15322 Aug 18
John Butler
EntityIndividual
Shares5,000
Max PriceUS$6.43

Ownership Breakdown


Management Team

  • Armando Anido (61yo)

    Chairman & CEO

    • Tenure: 4.8yrs
    • Compensation: $2.00m
  • Terri Sebree (61yo)

    President

    • Tenure: 4.8yrs
    • Compensation: $1.28m
  • Will Roberts (50yo)

    VP of Investor Relations & Corporate Communications

    • Tenure: 2.1yrs
  • Jim Fickenscher (55yo)

    CFO, VP of Corporate Development & Treasurer

    • Tenure: 2.9yrs
    • Compensation: $1.11m
  • Suzanne Hanlon (62yo)

    Secretary

    • Tenure: 4.8yrs
    • Compensation: $791.52k
  • Joseph Palumbo

    Chief Medical Officer


Board Members

  • Dan Kisner (72yo)

    Director

    • Tenure: 4.0yrs
    • Compensation: $158.11k
  • Jacqueline French

    Member of Scientific Advisory Board

  • Ken Moch (64yo)

    Director

    • Tenure: 4.0yrs
    • Compensation: $160.61k
  • Armando Anido (61yo)

    Chairman & CEO

    • Tenure: 4.8yrs
    • Compensation: $2.00m
  • Steven Siegel

    Member of Scientific Advisory Board

  • John Messenheimer

    Member of Scientific Advisory Board

  • Warren Cooper (66yo)

    Lead Independent Director

    • Tenure: 3.8yrs
    • Compensation: $179.48k
  • Pamela Stephenson (51yo)

    Director

    • Tenure: 0.5yrs
  • Bill Federici (59yo)

    Director

    • Tenure: 4.0yrs
    • Compensation: $166.86k
  • Rodney Radtke

    Member of Scientific Advisory Board

Company Information

Zynerba Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Zynerba Pharmaceuticals, Inc.
  • Ticker: ZYNE
  • Exchange: NasdaqGM
  • Founded: 2007
  • Industry: pharmaceuticals
  • Sector: pharmaceuticals & biotech
  • Market Cap: US$259.688m
  • Shares outstanding: 23.19m
  • Website: Click here

Number of Employees


Location

  • Zynerba Pharmaceuticals, Inc.
  • 80 West Lancaster Avenue
  • Suite 300
  • Devon
  • Pennsylvania
  • 19333
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ZYNENasdaqGM (Nasdaq Global Market)YesCommon StockUSUSDAug 2015
6ZYDB (Deutsche Boerse AG)YesCommon StockDEEURAug 2015
0M40LSE (London Stock Exchange)YesCommon StockGBUSDAug 2015

Biography

Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. It focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neur ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/08/18 01:04
End of Day Share Price2019/08/16 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.